Canasa

Phase 3Small molecule

Novartis

Canasa is one of 8 small molecule programs targeting Proctitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProctitisActive, not recruiting

ProctitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Proctitis

#DrugCompanyPhaseTrials

Lialda

Takeda

Approved

—2

Prograf

VVeloxis Pharmaceuticals

Approved

1 3

Thalomid

Bristol-Myers Squibb

Phase 2

1 4

Pulmicort

SSalix

Phase 2

2 5

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 2

1 6

Canasa

Novartis

Phase 3

1 7

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Phase 1

2 8

Mesalazine

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Proctitis1 trial

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

Terminated·FForest Laboratories·Phase 3·NCT01016262·119 enrolled

Clinical Trial1 trial

Clinical Trial With Mesalamine 1g Suppositories

Terminated· Novartis logo

Novartis·Phase 3·NCT01172444·158 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Canasa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Canasa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Canasa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Canasa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Proctitis1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News